The Inflammatory Profile of CTEPH-Derived Endothelial Cells Is a Possible Driver of Disease Progression

Valérie F E D Smolders1,2, Kirsten Lodder2, Cristina Rodríguez3,4

  • 1Department of Surgery, Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.

Cells
|April 3, 2021
PubMed

Insights

Chronic thromboembolic pulmonary hypertension (CTEPH) involves inflamed endothelial cells (ECs). Blocking the NF-κB pathway reduces inflammatory factors in CTEPH-ECs, suggesting its role in disease progression.

Area of Science:

  • Cardiovascular Biology
  • Pulmonary Hypertension Research
  • Endothelial Cell Biology

Background:

  • Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by pulmonary artery obstruction.
  • Endothelial cell (EC) dysfunction and inflammation are implicated in CTEPH pathogenesis.
  • The regulation of basal EC inflammation in CTEPH is not fully understood.

Purpose of the Study:

  • To investigate the role of the nuclear factor (NF)-κB pro-inflammatory signaling pathway in CTEPH endothelial cells under basal conditions.
  • To determine if NF-κB activation contributes to the pro-inflammatory status of CTEPH endothelial cells.

Main Methods:

  • Compared basal mRNA levels of inflammatory markers (IL-8, IL-1β, MCP-1, CCL5, VCAM-1) in CTEPH-ECs versus control ECs.
  • Utilized the NF-κB inhibitor Bay 11-7085 to assess pathway involvement.
  • Stained pulmonary endarterectomy (PEA) specimens and isolated ECs for phospho-NF-κB-P65 to confirm NF-κB activation.

Main Results:

  • CTEPH-ECs exhibited upregulated basal mRNA levels of key pro-inflammatory cytokines and adhesion molecules compared to controls.
  • Inhibition of NF-κB signaling abolished the increased production of pro-inflammatory cytokines in CTEPH-ECs.
  • Phospho-NF-κB-P65 was detected in vessels within thrombi and in CTEPH-ECs from PEA specimens, indicating NF-κB activation.

Conclusions:

  • CTEPH endothelial cells possess a basal pro-inflammatory state.
  • NF-κB signaling activation is a key regulator of this basal inflammation in CTEPH-ECs.
  • Targeting NF-κB signaling may offer a therapeutic strategy for CTEPH by reducing inflammation and potentially impacting disease progression.